Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo

Afatinib, a second-generation tyrosine kinase inhibitor (TKI), has been approved for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). However, afatinib’s clinical application is still hampered by acquired resistance. Recently, autophagy is considered as an important mechanis...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiangxiang, Shi, Si, Wang, Huan, Yu, Xiaochen, Wang, Qian, Jiang, Shanshan, Ju, Dianwen, Ye, Li, Feng, Meiqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496850/
https://www.ncbi.nlm.nih.gov/pubmed/28676644
http://dx.doi.org/10.1038/s41598-017-04258-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496850/
https://www.ncbi.nlm.nih.gov/pubmed/28676644
http://dx.doi.org/10.1038/s41598-017-04258-8

Ejemplares similares